An Analysis of a Phase II Study of Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer
Adam M. Brufsky, MD, PhD, discusses the results of a study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or MBC.
Clinical Pearls
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses the results of a phase II study that looked at the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.
- Eribulin has demonstrated a survival advantage in HER2-negative metastatic breast cancer.
- In this phase II trial, 52 patients received eribulin and trastuzumab for a median treatment duration of about 30 weeks. Twenty-one patients had received prior trastuzumab.
- Objective response rates were high, regardless of treatment with prior trastuzumab (ORR = 62%) or not (ORR = 77%).
- Activity has been demonstrated in the first-line, though Brufsky anticipates there will be activity across all lines of therapy.
<<<
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More
